DE69737749D1 - (-)-8-Ä(4-Amino-1-methylbutyl)aminoÜ-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylchinolin-enthaltendes Medikament zur Behandlung parasitärer und opportunistischer Infektionen - Google Patents

(-)-8-Ä(4-Amino-1-methylbutyl)aminoÜ-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylchinolin-enthaltendes Medikament zur Behandlung parasitärer und opportunistischer Infektionen

Info

Publication number
DE69737749D1
DE69737749D1 DE69737749T DE69737749T DE69737749D1 DE 69737749 D1 DE69737749 D1 DE 69737749D1 DE 69737749 T DE69737749 T DE 69737749T DE 69737749 T DE69737749 T DE 69737749T DE 69737749 D1 DE69737749 D1 DE 69737749D1
Authority
DE
Germany
Prior art keywords
amino
methylquinoline
dichlorophenoxy
methylbutyl
parasitic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69737749T
Other languages
English (en)
Other versions
DE69737749T2 (de
Inventor
James D Mcchesney
Dhammika N P Nanayakkara
Marilyn Bartlett
Arba L Ager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Mississippi
Original Assignee
University of Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Mississippi filed Critical University of Mississippi
Publication of DE69737749D1 publication Critical patent/DE69737749D1/de
Application granted granted Critical
Publication of DE69737749T2 publication Critical patent/DE69737749T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE69737749T 1996-03-29 1997-03-28 (-)-8-Ä(4-Amino-1-methylbutyl)aminoÜ-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylchinolin-enthaltendes Medikament zur Behandlung parasitärer und opportunistischer Infektionen Expired - Fee Related DE69737749T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1429296P 1996-03-29 1996-03-29
US14292P 1996-03-29
PCT/US1997/005160 WO1997036590A1 (en) 1996-03-29 1997-03-28 8-aminoquinolines

Publications (2)

Publication Number Publication Date
DE69737749D1 true DE69737749D1 (de) 2007-07-05
DE69737749T2 DE69737749T2 (de) 2008-01-31

Family

ID=21764604

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737749T Expired - Fee Related DE69737749T2 (de) 1996-03-29 1997-03-28 (-)-8-Ä(4-Amino-1-methylbutyl)aminoÜ-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylchinolin-enthaltendes Medikament zur Behandlung parasitärer und opportunistischer Infektionen

Country Status (11)

Country Link
US (1) US6376511B2 (de)
EP (1) EP0907363B1 (de)
AT (1) ATE362762T1 (de)
AU (1) AU729992B2 (de)
CA (1) CA2250501C (de)
DE (1) DE69737749T2 (de)
DK (1) DK0907363T3 (de)
ES (1) ES2284184T3 (de)
NZ (1) NZ332197A (de)
PT (1) PT907363E (de)
WO (1) WO1997036590A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210150D0 (en) 2002-05-03 2002-06-12 Smithkline Beecham Plc Process
US6949250B2 (en) * 2002-12-16 2005-09-27 The United States Of America As Represented By The Secretary Of Agriculture Selective algaecides for control of cyanochloronta
WO2007127930A2 (en) * 2006-04-28 2007-11-08 Kansas State University Research Foundation Compounds affecting gap junction activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB834300A (en) * 1957-03-22 1960-05-04 Wellcome Found Improvements in and relating to quinoline derivatives and the manufacture thereof
US4209519A (en) * 1978-03-13 1980-06-24 The United States Of America As Represented By The Secretary Of The Army Anti-leishmanial lepidine derivatives
US4431807A (en) * 1980-06-12 1984-02-14 The United States Of America As Represented By The Secretary Of The Army 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines
US4659708A (en) * 1980-09-02 1987-04-21 The United States Of America As Represented By The Secretary Of The Army Anti-leishmanial lepidine derivatives
US4554279A (en) * 1981-01-29 1985-11-19 The United States Of America As Represented By The Secretary Of The Army 5-(Straight chain 3-12 carbon alkoxy)-8-quinolinamines and their use for treatment of malaria
US4617394A (en) * 1985-10-15 1986-10-14 The United States Of America As Represented By The Secretary Of The Army 4-methyl-5-(unsubstituted and substituted phenoxy)-2,6-dimethoxy-8-(aminoalkylamino) quinolines
FR2612778B1 (fr) * 1987-03-24 1991-10-18 Ire Cell Targ Sa Nouveaux derives d'aminoquinoleine antimalarique, procede de preparation et composition pharmaceutique en contenant
FR2644462B1 (fr) * 1988-09-23 1993-07-09 Ire Celltarg Sa Nouveaux composes actifs sur les formes tissulaires de la malaria et procede de preparation
US5104885A (en) * 1990-03-13 1992-04-14 Calspan Corporation 5-(phenylalkoxy)primaquine and 5[(heterocycle)alkoxy] primaquine compounds and their use for treatment of malaria
US4980360A (en) * 1990-03-13 1990-12-25 Calspan Corporation 5-(phenylalkoxy)primaquine compounds and their use for treatment of malaria

Also Published As

Publication number Publication date
NZ332197A (en) 2000-06-23
PT907363E (pt) 2007-06-08
CA2250501C (en) 2007-11-13
WO1997036590A1 (en) 1997-10-09
ATE362762T1 (de) 2007-06-15
AU2596697A (en) 1997-10-22
US6376511B2 (en) 2002-04-23
CA2250501A1 (en) 1997-10-09
DK0907363T3 (da) 2007-09-24
EP0907363A4 (de) 2005-04-06
EP0907363B1 (de) 2007-05-23
DE69737749T2 (de) 2008-01-31
EP0907363A1 (de) 1999-04-14
ES2284184T3 (es) 2007-11-01
AU729992B2 (en) 2001-02-22
US20010007031A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
FI961809A (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
EP0765160A4 (de)
GEP20002211B (en) Taxoids, Preparation Thereof, Pharmaceutical Compositions Containing Same
CA2462453A1 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
CA2214026A1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
HU9402933D0 (en) Neurotensine-receptor-active 1-naphtyl-pyrazol-3-carboxamides process for producing them and pharmaceutical compositions containing them as active components
YU78302A (sh) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
AU1185801A (en) Novel compounds
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
DE69737749D1 (de) (-)-8-Ä(4-Amino-1-methylbutyl)aminoÜ-5-(3,4-dichlorophenoxy)-6-methoxy-4-methylchinolin-enthaltendes Medikament zur Behandlung parasitärer und opportunistischer Infektionen
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
IL110011A0 (en) Pharmaceutical compositions for the treatment of schizophrenia
RS4904A (en) Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
HUP9701618A2 (hu) Tramadolt és valamely kálciumcsatorna antagonistát tartalmazó gyógyászati készítmény
MD1738F2 (ro) Sare de diclavulanat, procedeu de obţinere şi compoziţie farmaceutică pe baza ei
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
MY138319A (en) 1,5-benzodiazepine derivatives
ES2184285T3 (es) Compuestos farmaceuticos que contienen diclorhidrato de cinconina.
AUPP429398A0 (en) A compound, WF002, production thereof and use thereof
BG106428A (en) Pharmaceutical compositions for treating psoriasis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee